SynthesisBMC cancer2025
Therapeutic efficacy of multiple neoadjuvant regimens involving targeted therapy, immunotherapy and chemotherapy in gastric cancer: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global hotspots and trends in the application of neoadjuvant therapy for gastric cancer: a bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Article
- Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Advances in the molecular subtyping of gastric cancer.World journal of surgical oncology · 2026Review
- Preoperative electrolyte-based metabolic biomarkers for prognostic assessment in gastric cancer: a multicenter study.Frontiers in endocrinology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroudThe utilization of neoadjuvant therapy, encompassing chemotherapy, molecular targeted therapy, and immunotherapy, has demonstrated a significant enhancement in the radical resection rate and an improved prognosis for patients with locally advanced gastric cancer (LAGC). The purpose of this meta-analysis was to evaluate the efficacy and safety of neoadjuvant chemotherapy (NCT) in combination with targeted therapy or (and) immunotherapy for LAGC patients.
methodsThe PubMed, EmBase, and Cochrane Library databases were systematically searched to identify clinical studies comparing the efficacy of different neoadjuvant regimens in LAGC patients. Subsequently, paired and network meta-analyses were conducted using Stata software to evaluate the pooled results of different neoadjuvant regimens, including NCT, neoadjuvant immunotherapy plus chemotherapy (NICT), NCT plus targeted therapy (NCTT), and NICT plus targeted therapy (NICTT).
results21 studies [six randomized controlled trials (RCTs) and 15 non-RCTs] fulfilled the inclusion criteria were incorporated into the meta-analysis. Pairwise meta-analysis revealed that the NICTT, NICT, and NCTT groups exhibited a higher incidence of pathological complete response (pCR), major pathological response (MPR), and R0 resection compared to the NCT group. Compared to the NCT group, both the NICTT and NCTT groups demonstrated a tendency towards experiencing more severe treatment-related adverse events (TRAEs), while the NICT and NCTT groups exhibited a lower 2-year recurrence rate. Additionally, network meta-analysis revealed that the NICTT group exhibited superior efficacy in achieving pCR, albeit being associated with a higher incidence of severe TRAEs.
conclusionCompared to NCT alone, the combined application of targeted therapy and/or immunotherapy demonstrates greater efficacy in tumor downstaging and achieving pCR. However, it is crucial to remain vigilant regarding the occurrence of severe TRAEs. The future adoption of NICTT as a mainstream treatment is anticipated, however, further high-quality clinical studies are imperative to substantiate its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.